What is Dyne Therapeutics, Inc.'s long-term debt?

Dyne Therapeutics, Inc. (DYN) reported long-term debt of $149.38M in Q1 2026.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Dyne Therapeutics, Inc. DYN Long-Term Debt

Long-Term Debt at other companies

Scholar RockSRRK

$196.61M+295%

BiogenBIIB

$6.29B+38.2%

CytokineticsCYTK

$247.21M+169%

ModernaMRNA

$590M—

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Operating income-$125.3M-2.4%

Net income-$120.9M-4.8%

EPS (diluted)-$0.73+30.5%

Balance sheet

See full

Cash & equivalents$753.1M+59.5%

Total debt$168.7M+623%

Total equity$865.1M+29.3%

Total assets$1.1B+49.8%

Cash flow

See full

Operating cash flow-$144.9M-36.9%

CapEx$221.0K-77.5%

Free cash flow-$145.1M-35.8%

Valuation

See full

Market cap$3.27B+153%

Enterprise value$2.69B+228%

Returns & leverage

See full

Return on equity-58.9%-4.4pp

Debt / equity0.2×+0.2×

Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s long-term debt?: Dyne Therapeutics, Inc. (DYN) reported long-term debt of $149.38M in Q1 2026.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.